tiprankstipranks
Advertisement
Advertisement

ARWR Stock Latest News

Buy Rating Reiterated on Arrowhead as Cardiometabolic RNAi Portfolio Advances; $100 Price Target Maintained
RatingsBuy Rating Reiterated on Arrowhead as Cardiometabolic RNAi Portfolio Advances; $100 Price Target Maintained
10d ago
ARWR
Arrowhead receives MAA in the EU for REDEMPLO
PremiumThe Fly
Arrowhead receives MAA in the EU for REDEMPLO
19d ago
ARWR
Arrowhead Pharmaceuticals Adds Experienced Healthcare Investor to Board
PremiumCompany Announcements
Arrowhead Pharmaceuticals Adds Experienced Healthcare Investor to Board
25d ago
8K
ARWR
Entera Bio Is Building the Future of Peptides Beyond the Needle (NASDAQ: ENTX)
PremiumTipRanks Newswire
Entera Bio Is Building the Future of Peptides Beyond the Needle (NASDAQ: ENTX)
1M ago
NVO
ARWR
Arrowhead’s Inhaled ARO-RAGE Asthma Trial Enters Active Recruitment, Keeping a Key Pipeline Catalyst in Play
PremiumCompany Announcements
Arrowhead’s Inhaled ARO-RAGE Asthma Trial Enters Active Recruitment, Keeping a Key Pipeline Catalyst in Play
1M ago
ARWR
Arrowhead Pharmaceuticals: Buy Rating Reaffirmed as ARO-INHBE Data Strengthen Outlook and $100 Price Target Maintained
PremiumRatingsArrowhead Pharmaceuticals: Buy Rating Reaffirmed as ARO-INHBE Data Strengthen Outlook and $100 Price Target Maintained
1M ago
ARWR
Arrowhead presents interim results from Phase 1/2a trial of ARO-INHBE
Premium
The Fly
Arrowhead presents interim results from Phase 1/2a trial of ARO-INHBE
2M ago
ARWR
Arrowhead presents clinical cardiometabolic data at EAS Congress
Premium
The Fly
Arrowhead presents clinical cardiometabolic data at EAS Congress
2M ago
ARWR
Arrowhead’s ARO-C3 Kidney Trial Reaches Completion, Setting Up the Next Catalyst for ARWR Investors
PremiumCompany Announcements
Arrowhead’s ARO-C3 Kidney Trial Reaches Completion, Setting Up the Next Catalyst for ARWR Investors
2M ago
ARWR
Arrowhead’s ARO-CFB Kidney Trial Completion: What Investors Should Watch Next
PremiumCompany Announcements
Arrowhead’s ARO-CFB Kidney Trial Completion: What Investors Should Watch Next
2M ago
ARWR
Arrowhead price target raised to $46 from $35 at Bernstein
PremiumThe Fly
Arrowhead price target raised to $46 from $35 at Bernstein
2M ago
ARWR
Arrowhead Pharmaceuticals’ Earnings Call: Launch, Losses, Bets
PremiumCompany Announcements
Arrowhead Pharmaceuticals’ Earnings Call: Launch, Losses, Bets
2M ago
ARWR
Arrowhead price target raised to $90 from $80 at Chardan
PremiumThe FlyArrowhead price target raised to $90 from $80 at Chardan
2M ago
ARWR
Arrowhead reports Q2 EPS (93c), consensus ($1.11)
Premium
The Fly
Arrowhead reports Q2 EPS (93c), consensus ($1.11)
2M ago
ARWR
Arrowhead announces exclusive worldwide license agreement with Madrigal Pharma
Premium
The Fly
Arrowhead announces exclusive worldwide license agreement with Madrigal Pharma
2M ago
ARWR
MDGL
Is ARWR a Buy, Before Earnings?
PremiumPre-Earnings
Is ARWR a Buy, Before Earnings?
2M ago
ARWR
Arrowhead announces Australian TGA approved Redemplo for FCS
PremiumThe Fly
Arrowhead announces Australian TGA approved Redemplo for FCS
2M ago
ARWR
Arrowhead initiated with an Overweight at JPMorgan
PremiumThe Fly
Arrowhead initiated with an Overweight at JPMorgan
2M ago
ARWR
Arrowhead, Astera, Exxon, Intel, Halliburton Trending With Analysts
PremiumWeekend Updates
Arrowhead, Astera, Exxon, Intel, Halliburton Trending With Analysts
3M ago
HAL
XOM
Arrowhead announces EMA recommended approval of Redemplo
PremiumThe FlyArrowhead announces EMA recommended approval of Redemplo
3M ago
ARWR
Intel upgraded, Reddit initiated: Wall Street’s top analyst calls
Premium
The Fly
Intel upgraded, Reddit initiated: Wall Street’s top analyst calls
3M ago
CL
MHK
Arrowhead upgraded to Overweight from Equal Weight at Morgan Stanley
Premium
The Fly
Arrowhead upgraded to Overweight from Equal Weight at Morgan Stanley
3M ago
ARWR

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >